Form 4: Catalyst Pharmaceuticals Director Molly Harper Reports Stock Transactions

Director Molly Harper reports the vesting and delivery of restricted stock units resulting in the acquisition and disposal of Catalyst Pharmaceuticals common stock.

Summary

• On February 14, 2025, Molly Harper, a director of Catalyst Pharmaceuticals, reported transactions involving restricted stock units (RSUs).
• 4,000 shares were acquired through the vesting of RSUs.
• Simultaneously, 6,746 shares were disposed of.
• Following these transactions, Harper directly owns 127,274 shares of Catalyst Pharmaceuticals common stock.
• The RSUs vested in three equal tranches on February 14, 2023, February 14, 2024, and February 14, 2025.
• The final tranche of shares was delivered on February 14, 2025.

Sentiment

Score: 5

Explanation: This is a neutral report of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency to the market regarding the trading activities of company directors.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a director.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates